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Introduction: Clinical dormancy is frequently observed in breast cancer. In the present study, we aimed to
characterize circulating tumor cells (CTCs) in dormancy candidates (DC) with early breast cancer in terms of
proliferation and apoptosis.
Methods: Cytospins of peripheral blood mononuclear cells (PBMCs) were obtained from DC (n = 122) who were
disease-free for at least 5 years and from metastatic patients (n = 40) who relapsed more than 5 years after surgery.
Sequential samples from eight DC (n = 36) who maintained a prolonged disease-free status and from eight DC
(n = 27) presenting late relapse during follow-up, were also analyzed. PBMCs were triple stained with a pancytokeratin,
antibody along with anti-Ki67 and anti-M30 antibodies as proliferation and apoptosis markers, respectively.
Results: CTCs were identified in 40 (33%) of 122 DC and in 15 (37.5%) of 40 metastatic patients. In total, twenty-five
(62.5%) DC had exclusively dormant (Ki67(-)/M30(-)), seven (17.5%) had proliferative Ki67(+)/M30(-), four (10%) had
apoptotic Ki67(-)/M30(+) and four (10%) had both phenotypes of proliferative and apoptotic CTCs. In comparison,
53.4% of CTC-positive metastatic patients had exclusively dormant and 46.6% had proliferative CTCs; none had
apoptotic CTCs (P = 0.039). Among all CTCs detected in DC patients, 82.4% were dormant, whereas in the nondormant
population, 32.5% were proliferative and 67.5% apoptotic. The respective percentages in metastatic patients were
59.1%, 100% and 0% (P <0.0001). Moreover, apoptotic CTCs prevailed among nondormant CTCs detected in sequential
samples from DC who remained in a prolonged disease-free status compared to those presenting late relapse during
follow-up (70.6% versus 43.5% (P = 0.0002)).
Conclusions: The apoptotic index of CTCs is increased during clinical dormancy, whereas the proliferation index is
increased on relapse. In addition, apoptotic CTCs are more frequently encountered during follow-up in DC patients who
remain disease-free compared to those with subsequent late relapse, suggesting that monitoring proliferation and
apoptosis in CTCs during clinical dormancy merits further investigation as a tool for predicting late disease recurrence.* Correspondence: agelaki@med.uoc.gr
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In breast cancer, relapses frequently occur many years or
even decades after surgical removal of the primary tumor
[1-3]. During the interval preceding relapse, patients have
no clinical or radiological evidence of metastases by the use
of standard work-up evaluations. In these patients, recur-
rence is thought to originate from cells that disseminated
from the primary tumor and underwent a period of disease
inactivity, termed dormancy, followed by a second period
of active growth. These disseminated tumor cells can per-
sist either as solitary dormant cells, which are quiescent,
undergoing neither cell division nor apoptosis [4-6], or as
dormant micrometastases, in which proliferation is bal-
anced by apoptosis [7]. This hypothesis has been supported
by mathematical modeling of breast cancer recurrence,
showing that dormancy represents a period of cancer quies-
cence followed by active growth, rather than a phase of lin-
ear tumor progression [8-10].
The detection of circulating tumor cells (CTCs) in the
blood or disseminated tumor cells (DTCs) in the bone
marrow in clinically disease-free patients with early
breast cancer as well as their association with worse pa-
tient prognosis has been well established [11-16]. Fur-
thermore, after the completion of adjuvant treatment, a
significant percentage of patients still harbor detectable
tumor cells in the blood and/or bone marrow, and their
presence remains an unfavorable prognostic factor
[17-23]. In these studies, patients were evaluated shortly
after the completion of adjuvant treatment or within
3 years after primary diagnosis [17,18,21] when the risk
of recurrence is presumably higher [24]. However, in
breast cancer, especially for patients with hormone
receptor-positive disease undergoing adjuvant hormone
therapy for 5 or more years, more than one-half of all
recurrences and deaths occur beyond 5 years from diag-
nosis [3,25] whereas, from 10 to 20 years, the rate of re-
lapse is relatively steady at about 1.5% yearly [26,27].
In a report by Meng et al., CTCs were detected in
breast cancer patients who had no evidence of disease, 7
to 22 years after mastectomy [28]. In a recent study that
included 312 patients with early breast cancer monitored
for cytokeratin (CK)-19 mRNA positivity in peripheral
blood during follow-up, we reported that 53.8% of pa-
tients had detectable CK-19 mRNA CTCs on at least
one time point between the third and fifth year of
follow-up and that persistence of CK-19 mRNA-positive
CTCs during the first 5 years was associated with in-
creased risk for late relapse and death [29]. However, it
is evident that despite the presence of CTCs the devel-
opment of metastases is not universal in all patients; the
early recognition of patients who are at increased risk
for recurrence remains an unmet need.
Although the precise mechanisms of breast cancer dor-
mancy are still unclear, cellular markers are available toidentify dormant CTCs. In experimental models, dormant
cells are described as viable cells lacking the expression of
both proliferative and apoptotic markers [5,30]. In addition,
evidence exists for a link between tumor dormancy and
apoptosis [7], whereas in another report, a dormant tumor
population was generated by balanced cell replication and
cell death [28]. In the current study, we sought to detect
CTCs in dormancy candidate (DC) patients with breast
cancer, which were defined as patients who remained free
of disease for at least 5 years following surgery, and to
characterize their apoptotic and proliferative status by the
use of a triple immunofluorescence method. Our results
demonstrate that monitoring proliferation and apoptosis in
CTCs could serve as a useful tool for the long-term follow-
up of primary breast cancer patients.
Methods
Patients
Women with stage I to III early breast cancer (n = 122) who
were under surveillance and had not experienced disease
relapse during the first 5 years of follow-up (defined as dor-
mancy candidates; DC), were eligible for this study. All pa-
tients had received adjuvant chemotherapy mostly in the
context of research protocols of the Hellenic Oncology Re-
search Group. After completion of adjuvant chemotherapy,
patients received adjuvant radiotherapy and hormonal ther-
apy when indicated according to their individual disease
characteristics. There were no subgroups of patients who re-
ceived hormone therapy only or no systemic therapy at all.
Patients’ follow-up consisted of pertinent medical his-
tory and physical examination, with laboratory and im-
aging studies restricted as indicated, every 3 months for
the first 2 years, every 6 months for the next 3 years and
yearly thereafter. Breast cancer patients (n = 40) present-
ing metastatic relapse more than 5 years after surgery
were evaluated before the initiation of any systemic first-
line therapy as a control group. In addition, sequential
follow-up samples were evaluated in 16 out of 40 CTC
DC identified as CTC-positive; eight of them had experi-
enced late disease relapse and eight had remained
disease-free during the whole follow-up period. Periph-
eral blood was also drawn from healthy female donors
(n = 15) who had neither known illness at the time of
sampling nor any history of malignant disease to ensure
the specificity of the methods used. All patients and
healthy volunteers gave their informed consent to par-
ticipate in the study, which has been approved by the
Ethics and Scientific Committees of the University Gen-
eral Hospital of Heraklion.
Cell cultures
The breast cancer cell lines SKBR3 and MDA-MB231 were
obtained from the American Type Culture Collection
(Manassas, VA, USA). Cells were centrifuged on cytospins
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be used as controls for CK, M30 and Ki67 staining experi-
ments, respectively.
SKBR3 cells were cultured in McCoy’s 5A GlutaMAX
supplemented with 10% fetal bovine serum (FBS) (Gibco
BRL Life Technologies, Rockville, MD, USA). MDA-MB231
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) GlutaMAX supplemented with 10% FBS. Cells
were maintained in a humidified atmosphere of 5% CO2 in
air. Subcultivation was performed with 0.25% trypsin and
5 mM EDTA (Gibco BRL Life Technologies).
SKBR3 cells were cultured in the presence or absence
of staurosporine 2μΜ (Merck, Darmstadt, Germany) for
2 hours to induce apoptotic events in drug-treated cells
[31]. Twenty to twenty-four hours prior to the experi-
ments, cells were transferred in serum-free medium.
After incubation with staurosporine, cells were centri-
fuged on cytospins according to the same procedure
followed for patients’ samples and were used as positive
controls for CK and M30 expression.
Cyto-centrifuged MDA-MB231 cells were used as posi-
tive controls for CK and Ki67 expression. All experiments
were performed during the logarithmic growth phase of
cells.
Sample collection and cytospin preparation
Twenty milliliters of blood were obtained from each patient
and healthy volunteers. To avoid blood contamination by
epithelial cells from the skin, all blood samples were col-
lected after the first 5 ml of blood were discarded. Peripheral
blood mononuclear cells (PBMCs) were isolated with Ficoll-
Hypaque density gradient (d =1.077 g/mol) centrifugation at
1,800 rpm for 30 minutes. PBMCs were washed three times
with phosphate-buffered saline (PBS) solution and centri-
fuged at 1,500 rpm for 10 minutes. Aliquots of 500,000 cells
were centrifuged at 2.000 rpm for 2 minutes on glass slides.
Cytospins were dried up and stored at -80°C. A total of 106
PBMCs were analyzed per patient. Results are expressed as
number of CTCs/500,000 PBMCs.
Characterization of M30 and Ki67 staining on SKBR3 and
MDA-MB231 breast cancer cell lines
To evaluate apoptosis with a staining procedure in a
model system, SKBR3 cells treated in the presence or
absence of staurosporine were used. Apoptosis was deter-
mined by staining with the M30 fluorescein-conjugated
mouse monoclonal antibody (CytoDEATH fluorescein;
Roche, Manheim, Germany). M30 recognizes the respect-
ive neoepitope exposed only after a specific caspase cleav-
age within cytokeratin 18 during early apoptosis [32].
Epithelial forms of positivity for this marker include cyto-
plasmic filamentous staining or granular aggregates as
shown in Figure 1A. Viable and necrotic cells and late
apoptotic epithelial cells are negative for M30.The expression of Ki67 as a proliferation marker [33] was
first evaluated using the MDA-MB231 breast cancer cell
line. Proliferative cells were detected using the specific anti-
Ki67 mouse antibody ab8191 (Abcam, Cambridge, UK).
For the Ki67 reactivity, the positive nuclear staining was
evaluated (Figure 1B).
CK positivity in cytospins of SKBR3 or MDA-MB231
cells was detected using the pancytokeratin rabbit anti-
body sc-15367 (Santa Cruz Biotechnology, Dallas, TX,
USA) [34-36]. Cell cytospins were evaluated using the au-
tomated image analysis (ARIOL) system CTCs software
(Genetix, New Milton, UK) [37].
Triple immunofluorescence for simultaneous detection of
Ki67 and M30
CK-positive and M30-positive or Ki67-positive CTCs were
identified by triple immunofluorescence. Briefly, PBMC
cytospins were fixed using 100% ice-cold pure methanol
(-20°C) for 7 minutes at room temperature (RT). Cell
permeabilization was performed with 100% ice-cold pure
acetone (-20°C) for 3 minutes and followed by incubation
with blocking buffer (PBS/2% FBS) for 30 minutes. Cytos-
pins were washed with PBS and stained with anti-Ki67
mouse antibody diluted 1:50, overnight. This was followed
by the secondary anti-mouse Alexa 633 antibody (Molecu-
lar Probes, Invitrogen, Carlsbad, CA, USA). Subsequently,
cells were stained with the pancytokeratin rabbit antibody
sc-15367 (Santa Cruz Biotechnology) diluted 1:50 [34-36],
followed by the secondary anti-rabbit Alexa 555 (Molecu-
lar Probes, Invitrogen). Afterward, cells were stained with
M30 fluorescein-conjugated mouse antibody diluted 1:100
for 90 minutes, in order to avoid cross-reaction with the
secondary anti-mouse Alexa 633 antibody. Finally, 4’,6-
diamidino-2-phenylindole (DAPI) antifade reagent (Invi-
trogen) was added to each sample for nuclear staining. To
ensure the performance of Ki67 and M30 staining, cytos-
pins of MDA-MB231 and SKBR3 staurosporine-treated
cells were included in each separate experiment as positive
controls. Negative controls, prepared by omitting the cor-
responding primary antibody and adding the secondary
immunoglobulin G (IgG) isotype antibody, were also used
in each separate experiment.
Specific staining was easily distinguished by the differen-
tial intracellular distribution of the examined molecules
(Figure 2A, B). Moreover, the cytomorphological and
immunophenotypic criteria proposed by Meng and col-
leagues (that is high nuclear to cytoplasmic ratio, cells lar-
ger than white blood cells, and so on; [28]) were used to
characterize a CK-positive cell as a CTC. In the evaluation
of the samples prepared from healthy female donors, CK-
negative cells expressing either Ki67 or M30 were detected.
On the contrary, there were no CK-positive cells identified
in any of these samples. To further confirm the specificity
of the method for cytokeratin detection, 106 PBMCs from
Figure 1 Expression of cytokeratin and M30 or cytokeratin and Ki67 in SKBR3 and MDA-MB231 breast cancer cell lines respectively.
(A) Staurosporine-treated SKBR3 cells were triple stained with pancytokeratin rabbit antibody/secondary anti-rabbit Alexa Fluor 555 (orange), anti-Ki67
mouse antibody/secondary anti-mouse Alexa 633 (red) and M30 mouse FITC-conjugated antibody (green). Cell nuclei were stained with DAPI (blue).
Images were obtained by the use of ARIOL system (X60). (B) MDA-MB231 cells were triple stained as described above. The positive nuclear dotted
staining (red) was evaluated for Ki67 staining. Images were obtained by the use of ARIOL system (X60). ARIOL system, automated image analysis
system; DAPI, 4’,6-diamidino-2-phenylindole; FITC, fluorescein isothiocyanate.
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rabbit control antibody to evaluate nonspecific staining. We
were not able to detect any event in these samples fulfilling
all the criteria described above for a CTC. All cytospins
were evaluated using the ARIOL microscopy system.Statistical analysis
Since this is a noninterventional study, there is not a specific
statistical estimation of the sample size. Enrolled patients
represent a cohort of patients followed in our institution.
Data were analyzed using the GraphPad prism software
(version 6) (GraphPad Software, San Diego, CA, USA). Fre-
quencies were compared by Fisher’s exact test or chi-square
and nonparametric Mann-Whitney test.Results
Detection of CTCs in blood samples of dormancy
candidate patients
A cohort of 122 DC patients was evaluated for the pres-
ence of CTCs. The median interval from surgical removal
of the primary tumor till CTC evaluation was 6 years
(range, 5 to 19). CTCs were detected in 40 (33%) out of
122 patients. The demographics of CTC-positive and
CTC-negative patients are presented in Table 1.Expression of M30 and Ki67 on CTCs of dormancy
candidate patients
M30, as a marker of apoptosis, and Ki67, as a marker of
proliferation, were used to characterize CTCs. In 25
(62.5%) out of 40 CTC-positive patients, all detected
CTCs were negative for both Ki67 and M30 (Ki67
(-)/M30(-) CTCs) corresponding to dormant cells
[5,30]. In the remaining CTC-positive patients both dor-
mant and nondormant (proliferative or apoptotic) CTCs
were identified; seven (17.5%) had proliferative (Ki67
(+)/M30(-)) CTCs, four (10%) had apoptotic (Ki67
(-)/M30(+)) and four (10%) had both phenotypes be-
sides the dormant sub-population (Table 2).
A total of 244 CTCs were detected in the whole group
of DC (mean: 6.1 CTCs/patient, standard error of the
mean (SEM) ± 1.8). As shown in Table 2, 82.4% were
dormant, 11.9% apoptotic and 5.7% proliferative.
Among the nondormant population, the proportions of
proliferative/nondormant and apoptotic/nondormant
CTCs were 32.5% and 67.5%, respectively. There were
no CTCs that could be stained positive for both Ki67
and M30.
Three (12%) out of twenty-five patients (Group I,
Table 2) harboring exclusively dormant CTCs, and five
(45.4%) out of eleven patients with proliferative CTCs
Figure 2 Expression of the proliferation marker Ki67 and the apoptotic marker M30 in CTCs of patients with early breast cancer. (A)
Representative image of a CTC stained positive for the proliferation marker Ki67 along with PBMCs. (B) Representative image of a CTC stained
positive for the apoptotic marker M30. Cytospins were triple stained with pancytokeratin rabbit antibody/secondary anti-rabbit Alexa Fluor 555
(orange), anti-Ki67 mouse antibody/secondary anti-mouse Alexa 633 (red) and M30 mouse FITC-conjugated antibody (green). Cell nuclei were
stained with DAPI (blue). Images were taken by ARIOL system (X60). ARIOL system, automated image analysis system; CTCs, circulating tumor cells;
DAPI, 4’,6-diamidino-2-phenylindole; FITC, fluorescein isothiocyanate; PBMCs, peripheral blood mononuclear cells.
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(P= 0.04); recurrence was detected at 6 to 15 years (mean,
10 years) after surgical removal of the primary tumor.Characterization of the proliferative and apoptotic status
of CTCs in metastatic breast cancer patients relapsing at
least 5 years after surgery
A group of 40 metastatic breast cancer patients who
had relapsed after a median of 5 years (range, 5 to
10 years) from surgery were evaluated for the presence
of CTCs, prior to the initiation of any systemic first-line
therapy. CTCs were detected in 15 (37.5%) patients and
dormant CTCs were evident in all but one patient. Eight
(53.4%) patients harbored exclusively dormant CTCs,
whereas in 46.6% Ki67(+) CTCs were also detected
(P = 0.039 compared to DC) (Table 2). None of the pa-
tients harbored apoptotic CTCs.
A total of 142 CTCs were identified in the whole
group (mean: 9.4 CTCs/patient, SEM ± 6.6); 59.1% of
these cells were dormant and 40.9% were Ki67(+)
(P <0.0001 compared to DC) (Table 2). Since no apop-
totic CTCs were detected, the proportion of proliferative
CTCs among the nondormant population was 100%.Incidence of proliferative and apoptotic CTCs in
sequential follow-up samples of dormancy candidates
To monitor the kinetics of proliferative and apoptotic CTCs
during the period of dormancy, sequential follow-up sam-
ples were evaluated in the group of eight out of forty CTC-
positive DC who subsequently experienced late disease
relapse and in another group of eight DC who remained in
a prolonged disease-free status during the whole follow-up
period. The last group was selected according to the length
of follow-up time and/or the availability of comparable
numbers of sequential samples for evaluation. Median
disease-free interval from the surgical removal of the pri-
mary tumor was 10.5 years (range 6 to 15 years) for the first
group, whereas the median follow-up time was 11 years
(range 8 to 13 years) for the second group.
i. Group of DC with late relapse
A total of 27 serial samples (median three/patient
(range two to six)) were evaluated (Additional file 1).
Two (25%) of eight patients (#7, #8) had exclusively
dormant CTCs during the whole follow-up period,
two (25%) (#1, #6) had proliferative CTCs and four
(50%) (#2, #3, #4, #5) had proliferative as well as
apoptotic CTCs besides the dormant population
Table 1 Characteristics of dormancy candidates
CTC-positive CTC-negative
(n = 40) (n = 82) P
Age, years
Median (range) 52 (27-75) 57 (31-71) 0.133
N (%)
Menopausal status
Premenopausal 21 (52.5) 28 (34.1) 0.152
Postmenopausal 18 (45) 51 (62.2)
UN 1 (2.5) 3 (3.6)
HR status
ER(+) and/or PR(+) 26 (65) 48 (58.5) 0.212
ER(-)/PR(-) 12 (30) 24 (29.3)
UN 2 (5) 10 (12.2)
HER2 status
HER2(+) 9 (22.5) 12 (14.6) 0.252
HER2(-) 29 (72.5) 59 (72)
UN 2 (5) 11 (13.4)
Tumor size
T1 10 (25) 25 (30.5) 0.418
T2 21 (52.5) 45 (54.9)
T3 8 (20) 8 (9.7)
UN 1 (2.5) 4 (4.8)
Grade
I 0 (0) 1 (1.2) 0.938
II 18 (45) 40 (48.8)
III 17 (42.5) 33 (40.2)
Lobular 3 (7.5) 5 (6)
UN 2 (5) 3 (3.6)
Number of positive nodes
0 15 (37.5) 33 (40.2) 0.220
1-3 12 (30) 33 (40.2)
≥4 12 (30) 12 (14.6)
UN 1 (2.5) 4 (4.8)
CTCs, circulating tumor cells; ER, estrogen receptor; HER2, human epidermal
growth factor 2; HR, hormone receptor; PR, progesterone receptor;
UN, unknown.
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follow-up samples, 88% were dormant, 6.8% were
proliferative and 5.2% apoptotic (Additional file 1).
The proportions of proliferative/nondormant and
apoptotic/nondormant CTCs were 56.5% and 43.5%,
respectively.
ii. Group of DC with prolonged disease-free status
A total of 36 sequential samples were analyzed
(Additional file 1). Four (50%) of eight DC (#9, #13,
#14, #15) had exclusively dormant CTCs during the
whole follow-up period, one (12.5%) (#10) hadproliferative, one (12.5%) (#16) had apoptotic and
two (25%) (#11, #12) had both populations CTCs be-
side the dormant one (Table 4). Α total of 77 CTCs
were detected in all samples. Among them, 78%
were dormant (P = 0.028 compared to the relapsed
group), 6.5% were proliferative and 15.8% apoptotic
(P = 0.0029 compared to the relapsed group)
(Additional file 1). The proportions of proliferative/
nondormant and apoptotic/nondormant CTCs were
29.4% and 70.6%, respectively (P = 0.0002 compared to
the relapsed group).Evaluation of Ki67 and M30 status of CTCs at the time
points with significantly increased CTC numbers during
follow-up
As shown in Tables 3 and 4, a significant increase in CTC
counts was observed on six of the thirty-eight CTC-
positive follow-up samples. The mean CTC number at the
time of highest CTC value was 64 (SEM± 30.6) compared
to 2.4 (SEM± 0.5) for the remaining CTC positive samples
(P = 0.0001).
This robust increase in CTC counts, ranging from 22 to
215 CTCs, was observed in four (50%) out of eight DC with
subsequent late relapse (#2, #3, #4, #5, Table 3). Patient #2
with 80% of the nondormant CTC population expressing
Ki67 at the time of the highest CTC count relapsed 1.5 years
later. On the contrary, in the other three patients (#3, #4
and #5), presenting higher percentages of apoptotic (63.6%,
80%, 96.5%) compared to proliferative nondormant CTCs,
relapses occurred 2.5, 3 and 5 years later (Additional
file 2A).
In the group of patients that remained in prolonged
disease-free status during the follow-up period, only two
(25%) (#12 and #16, Additional file 2B) presented a sig-
nificant increase in CTC counts (22 and 31 CTCs, re-
spectively) at 3.5 and 0 years prior to the last evaluation;
in these patients 75% and 100% of the nondormant CTC
population was apoptotic. The remaining patients pre-
sented low CTC counts of dormant cells.Discussion
In the current study we observed that many patients
with breast cancer continue to have CTCs beyond 5 years
after surgery, despite the absence of clinical evidence of
disease recurrence. Herein we provide, to our knowledge
for the first time, an insight into the proliferative and
apoptotic status of these CTCs; we show that their great
majority are neither proliferative nor apoptotic, possibly
representing dormant cells. In addition, we demonstrate
that these patients also harbor nondormant CTCs and
that the dormancy state might be linked to increased
apoptosis, whereas escape from dormancy is associated
with increased proliferative index in CTCs.
Table 2 Incidence of proliferative and apoptotic CTCs in CTC-positive DC and metastatic patients and their percentages
among the total CTCs detected
CTC phenotype (n%)
Patient groups I II III IV
Dormant onlya Proliferativeb Apoptoticc All phenotypese
Dormancy candidates (n = 40) 25 (62.5) 7 (17.5) 4 (10) 4 (10)
Metastatic patients (n = 15) 8 (53.4) 7 (46.6)* 0 (0) 0 (0)
CTC phenotype (n %)
Dormanta Nondormantd
Number of CTCs Proliferativeb Apoptoticc
Dormancy candidates (n = 244) 201 (82.4) 14 (5.7) 29 (11.9)
Metastatic patients (n = 142) 84 (59.1)** 58 (40.9)** 0 (0)
Patients with aKi67(-)/M30(-) CTCs, bKi67(+)/M30(-) CTCs, cKi67(-)/M30(+) CTCs, dKi67(+)/M30(-) or Ki67(-)/M30(+) CTCs and epatients harboring all phenotypes.
*P = 0.0394, **P <0.0001, compared to dormancy candidates. CTCs, circulating tumor cells; DC, dormancy candidates.
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characterization of CTCs in early breast cancer patients
beyond the time frame of the first 5 years of follow up.
These patients were characterized as dormancy candi-
dates since they are likely to have CTCs in a dormant
state and, at the same time, are still at considerable risk
for recurrence and death from their disease. We used a
triple immunofluorescence technique in order to detect
CK-positive cells on PBMC cytospins and to evaluate
their proliferative and apoptotic status after staining
with Ki67 and M30 antibodies, respectively [38]. CTCs
were detected in 33% of 122 DC, in line with the report
by Meng et al. [28] where 36% of 36 dormancy candi-
dates had CTCs detected by immunocytochemistry, 7 to
22 years following surgery. Similarly, Payne et al. [39] re-
ported that measures of minimal residual disease, includ-
ing CTCs, were evident in patients with primary breast
cancer more than 4 years following surgical treatment.
Another objective of this study was the characterization of
CTCs in DC according to their proliferative and apoptotic
status. It is generally accepted that the majority of dissemi-
nated tumor cells found in the bone marrow or the circula-
tion of breast cancer patients are nonproliferative cells
[40,41]. In addition, different rates of apoptosis in DTCs or
CTCs have been reported according to the tumor type, the
disease stage and/or phase of treatment [42-46]. In our
study, CTCs lacking staining for the markers Ki67 or M30,
which are used to identify proliferative and apoptotic CTCs,
respectively, were characterized as dormant [5,30]. It should
be mentioned here that, although it is generally accepted
that Ki67 protein expression and cell proliferation are closely
linked, the dynamic expression of Ki67 in a cell determined
as Ki67 negative, cannot be ruled out. Indeed, it has been
suggested that Ki67 may remain undetectable during the G1
phase, therefore, the cell under evaluation could be incor-
rectly characterized as nonproliferative [47].
We showed that 27.5% and 20% of DC patients harbor
proliferative and apoptotic CTCs, respectively. However,most CTCs identified in the whole group were dormant,
whereas among the nondormant population, apoptotic
CTCs prevailed. Since the half-life of CTCs has been esti-
mated between 1 and 2.4 hours [28], our observations are
in line with the hypothesis that, during dormancy, CTCs
are most probably derived from undetected micrometa-
static deposits where a balance between proliferation and
apoptosis, in favor of the latter, exists [4,7]. Similarly, in
the report by Payne et al., apoptosis, as demonstrated by
an increase in larger-sized fragments in cell-free DNA,
was inversely related to the detection of DTCs in the bone
marrow, suggesting that this measure of micrometastatic
disease probably emerged from dying micrometastases
[39]. In preclinical models, apoptosis, through impaired
vascularization or immune-mediated mechanisms, has
been considered to be involved in the regulation of dor-
mancy [4,7,26]. Interestingly, in a mouse model of primary
chemical carcinogenesis, the immune system was shown
to restrain the net expansion of ‘dormant’ tumor cells and
this was characterized by a combination of increased
apoptosis and decreased tumor cell proliferation [48].
However, the simultaneous presence of DTCs prone to
mechanisms of cellular dormancy cannot be excluded.
In our study, metastatic patients who recurred after 5.5 to
10 years following surgery, were included as a control group
for the evaluation of CTCs in a condition that resembles es-
cape from dormancy. Although a relatively low CTC detec-
tion rate was observed among those patients [49], possibly
related to the limited number of patients analyzed, it was
shown that none had apoptotic CTCs at the time of disease
relapse. This is in agreement with the study by Fehm et al.,
where no apoptotic DTCs were detected in patients with
tumor progression after neoadjuvant chemotherapy [42]. In
addition, in metastatic patients, dormant CTC counts were
decreased and the proliferative index in CTCs was increased
as compared to dormancy candidates. Moreover, it is also of
interest that subsequent late relapses were recorded in
45.4% out of DC patients with proliferative CTCs compared
Table 3 Numbers of total, proliferative and apoptotic CTCs in serial samples during the dormancy period for DC with late relapse (n = 8)
Patient number Dormancy period (yrs) Test no/
(time since surgery yrs)








1 6 1/3 (5y) DF 1 100 0 0 0
2/3 (5.5y) DF 4 87.5 12.5 100 0
3/3 (6y) R 3 83.3 16.7 100 0
2 7 1/4 (5y) DF 12 50 50 100 0
2/4 (5.5y) DF 215 93 7 80 20
3/4 (6.5y) DF 2 50 50 100 0
4/4 (7y) R 1 0 0 100 0
3 10.5 1/5 (5.5y) DF 0 0 0 0 0
2/5 (6y) DF 0 0 0 0 0
3/5 (8y) DF 22 50 50 36.4 63.6
4/5 (10y) DF 0 0 0 0 0
5/5 (10.5y) R 0.5 100 0 0 0
4 9.5 1/5 (5y) DF 1 100 0 0 0
2/5 (5.5y) DF 9 89 11 0 100
3/5 (6.5y) DF 57 91.3 8.7 20 80
4/5 (7.5y) DF 1 100 0 0 0
5/5 (9.5y) R 0 0 0 0 0
5 11 1/4 (5y) DF 9.5 100 0 0 0
2/4 (6y) DF 38 87.3 12.7 3.5 96.5
3/4 (10y) DF 0 0 0 0 0
4/4 (11y) R 0 0 0 0 0
6 10.5 1/7 (5.5y) DF 0 0 0 0 0
2/7 (7y) DF 0 0 0 0 0
3/7 (7.5y) DF 0 0 0 0 0
4/7 (8y) DF 0 0 0 0 0
5/7 (9y) DF 2.5 60 40 100 0
6/7 (10y) DF 0.5 100 0 0 0
7/7 (10.5y) R 9 50 50 100 0
7 15 1/3 (11y) DF 5 100 0 0 0
2/3 (12y) DF 2 100 0 0 0










Table 3 Numbers of total, proliferative and apoptotic CTCs in serial samples during the dormancy period for DC with late relapse (n = 8) (Continued)
8 11 1/4 (6.5y) DF 0 0 0 0 0
2/4 (7y) DF 0 0 0 0 0
3/4 (7.5y) DF 1 100 0 0 0
4/4 (11y) R 0.5 100 0 0 0
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9 8 1 (5) DF 1 100 0 0 0
2 (5.5) DF 0 0 0 0 0
3 (6) DF 1 100 0 0 0
4 (6.5) DF 0 0 0 0 0
5 (7) DF 0 0 0 0 0
6 (7.5) DF 0 0 0 0 0
7 (8) DF 0 0 0 0 0
10 13 1 (5) DF 1.5 100 0 0 0
2 (8) DF 0 0 0 0 0
3 (11) DF 5 60 40 100 0
4 (12) DF 0.5 100 0 0 0
5 (13) DF 0.5 0 100 100 0
11 10 1 (7) DF 1 0 100 0 100
2 (8) DF 1 0 100 0 100
3 (9) DF 2 50 50 100 0
4 (10) DF 2 100 0 0 0
12 13 1 (5) DF 2 75 25 100 0
2 (5.5) DF 3.5 100 0 0 0
3 (9.5) DF 22 75 25 25 75
4 (10.5) DF 1 0 100 0 100
5 (11.5) DF 0 0 0 0 0
6 (12) DF 0 0 0 0 0
7 (13) DF 0 0 0 0 0
13 10.5 1 (5) DF 0.5 100 0 0 0
2 (9) DF 1 100 0 0 0
3 (10.5) DF 0 0 0 0 0
14 10.5 1 (5) DF 0 0 0 0 0
2 (6) DF 0.5 100 0 0 0
3 (10) DF 0 0 0 0 0
15 8 1 (5) DF 0.5 100 0 0 0
2 (5.5) DF 0 0 0 0 0
3 (6) DF 0.5 100 0 0 0
4 (8) DF 0 0 0 0 0
16 12 1 (10) DF 0 0 0 0 0
2 (11) DF 1 100 0 0 0
3 (12) DF 31 82 18 0 100
aKi67(-)/M30(-) CTCs, bKi67(+)/M30(-) CTCs, cKi67(-)/M30(+), dKi67(+)/M30(-) or Ki67(-)/M30(+) CTCs. CTCs, circulating tumor cells; DC, dormancy candidates;
DF, disease-free.
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Thus, escape from dormancy and late relapse could be asso-
ciated with increased proliferation in CTCs. In accordance,
studies using preclinical models suggest that escape from
dormancy is associated with cellular proliferation driven bymicroenvironmental signals leading to extracellular signal-
related kinase (ERK) activation [50,51].
We further evaluated the kinetics and the phenotype
of CTCs in sequential samples obtained during follow-
up from two groups of DC; from one that presented late
Spiliotaki et al. Breast Cancer Research  (2014) 16:485 Page 11 of 13relapse during follow-up and one that remained in a
prolonged disease-free status. This was considered of
importance since the fluctuations of these markers over
time had not been previously described, and could be in-
formative regarding subsequent disease recurrence.
It was shown that CTCs were intermittently present
during the evaluation period albeit at similar frequency
among patients in both groups. Interestingly, the group
of DC with prolonged disease-free status generally pre-
sented lower CTC counts on serial samples compared to
the group with late relapse, and this could be related to
the maintenance of dormancy. On the other hand, it
seems that the repetitive detection of CTCs does not ne-
cessarily indicate future relapse and points to the need
for further characterization of these CTCs. Thus, the
apoptotic index prevailed in the group with prolonged
disease-free status (that maintained dormancy). Another
interesting finding was that several patients presented, at
some point during follow-up, a robust increase in CTC
numbers involving both dormant and nondormant
CTCs. The balance between proliferation and apoptosis
at this time point could be associated with the time to
subsequent disease recurrence.
Our study has several limitations that should be consid-
ered. First, an overlap was observed in the detection of
proliferation and apoptosis markers between the relapse-
free DC and those who relapsed, representing a significant
limitation for their clinical use, especially when a sample
from a single time point is evaluated. Another limitation is
the retrospective nature of our study, the small number of
patients followed with serial samples, and the lack of
matching in terms of patient and disease characteristics
between the two groups. Moreover, it could be argued that
the actual CTC phenotype could not be reliably depicted
in cases with low CTC counts. Nevertheless, this is the
real case scenario, since in general, low CTC counts are
observed in patients with early disease [14]. Finally, al-
though in breast cancer the immunohistochemical assess-
ment of proliferation using the marker Ki67 is considered
important, both in clinical practice and research, substan-
tial interlaboratory variability limits its clinical use [52]. It
is conceivable that Ki67 evaluation of isolated cells could
be prone to similar drawbacks.
Conclusions
Our data suggest that breast cancer dormancy displays sig-
nificant differences compared to the overt metastatic state
regarding the incidence of dormant and nondormant CTCs
as well as the balance between proliferation and apoptosis
in CTCs. Moreover, in each patient, the dormancy period
seems to be characterized by variations in CTC load, in the
shift between dormant and nondormant populations and in
the balance between proliferative and apoptotic nondor-
mant CTCs. This balance could be associated with themaintenance of or the escape from clinical dormancy.
However, the observed variability in CTC detection rate as
well as in the expression of these parameters over time,
even among the same individual, precludes firm conclu-
sions to be drawn regarding their use in the prediction of
patient prognosis, at least as they stand in the current
study. Our findings are rather hypothesis generating and
merit further investigation in larger studies designed to
evaluate their clinical significance, either alone or as part of
a prognostic model, in order to define high-risk patient
subgroups that might benefit from extended or secondary
adjuvant treatments.
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